PTGX

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Wall Street analysts forecast PTGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 87.31 USD with a low forecast of 65.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Protagonist Therapeutics Inc revenue for the last quarter amounts to 4.71M USD, increased 0.79 % YoY.

Protagonist Therapeutics Inc. EPS for the last quarter amounts to -0.62 USD, increased 14.81 % YoY.

Protagonist Therapeutics Inc (PTGX) has 126 emplpoyees as of December 17 2025.

Today PTGX has the market capitalization of 5.72B USD.